Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity

Leukemia. 2014 Sep;28(9):1915-8. doi: 10.1038/leu.2014.141. Epub 2014 Apr 30.

Authors

R Pippa¹, A Dominguez¹, D J Christensen², I Moreno-Miralles¹, M J Blanco-Prieto³, M P Vitek², M D Odero⁴

Affiliations

¹ Hematology/Oncology Program, Center for Applied Medical Research (CIMA), University of Navarra, Navarra, Spain.
² Oncotide Pharmaceuticals, Research Triangle Park, NC, USA.
³ Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, Navarra, Spain.
⁴ 1] Hematology/Oncology Program, Center for Applied Medical Research (CIMA), University of Navarra, Navarra, Spain [2] Department of Biochemistry and Genetics, University of Navarra, Navarra, Spain.

PMID: 24781014
DOI: 10.1038/leu.2014.141

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cell Line, Tumor
DNA-Binding Proteins
Fingolimod Hydrochloride
Histone Chaperones / physiology*
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / enzymology
Peptides / pharmacology
Propylene Glycols / pharmacology*
Protein Phosphatase 2 / antagonists & inhibitors*
Sphingosine / analogs & derivatives*
Sphingosine / pharmacology
Transcription Factors / physiology*

Substances

DNA-Binding Proteins
Histone Chaperones
OP449 peptide
Peptides
Propylene Glycols
SET protein, human
Transcription Factors
Protein Phosphatase 2
Fingolimod Hydrochloride
Sphingosine